Primary Biliary Cholangitis Clinical Trial Pipeline Pharmaceutical companies are advancing the Primary Biliary Cholangitis treatment pipeli ...

Gilead Sciences, Inc. today announced that the European Commission (EC) has granted conditional marketing authorization for seladelpar for the treatment of primary biliary cholangitis (PBC) in ...

The FDA has granted Fast Track designation to ADI-001 for the treatment of refractory systemic lupus erythematosus with extrarenal involvement.

And guess what’s also found in joint tissues? GLP-1 receptors. So it turns out that GLP-1 drugs may be able to target and ease the low-grade local inflammation of the synovium that causes such ...

Depending on the severity, there are different therapeutic options (topical medications, phototherapy, systemic drugs, etc ... of the other adenosine receptors. "This activation has an anti ...

Get Instant Summarized Text (Gist) A new technology using a light-activated compound has been developed to target drug-resistant cancer cells by suppressing autophagy, a key resistance mechanism ...

Depending on the severity, there are different therapeutic options (topical medications, phototherapy, systemic drugs, etc ... of the other adenosine receptors. "This activation has an anti ...

Allurion (NYSE:ALUR) announced about ten minutes before the market's close that it is planning a study that will evaluate the Allurion Program with GLP-1 agonists in the improvement of overall ...

That hasn't stopped the drugs from racking up billions of dollars in annual sales of course, and Gilead will be hoping that MiroBio's approach of targeting immune inhibitory receptors will have ...